168 related articles for article (PubMed ID: 18464258)
1. Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Yang JL; Qu XJ; Yu Y; Kohn EC; Friedlander ML
Int J Cancer; 2008 Jul; 123(2):258-263. PubMed ID: 18464258
[TBL] [Abstract][Full Text] [Related]
2. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
de Castro E Gloria H; Jesuíno Nogueira L; Bencke Grudzinski P; da Costa Ghignatti PV; Guecheva TN; Motta Leguisamo N; Saffi J
BMC Cancer; 2021 Apr; 21(1):448. PubMed ID: 33888065
[TBL] [Abstract][Full Text] [Related]
3. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression and cell cycle response in DNA mismatch repair-deficient cells upon methylation and UV-C damage.
Lützen A; Bisgaard HC; Rasmussen LJ
Exp Cell Res; 2004 Jan; 292(1):123-34. PubMed ID: 14720512
[TBL] [Abstract][Full Text] [Related]
5. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
Adamsen BL; Kravik KL; De Angelis PM
Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
[TBL] [Abstract][Full Text] [Related]
6. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures.
Shakibaei M; Buhrmann C; Kraehe P; Shayan P; Lueders C; Goel A
PLoS One; 2014; 9(1):e85397. PubMed ID: 24404205
[TBL] [Abstract][Full Text] [Related]
7. Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1.
Vernole P; Muzi A; Volpi A; Terrinoni A; Dorio AS; Tentori L; Shah GM; Graziani G
Mutat Res; 2011 Jul; 712(1-2):40-8. PubMed ID: 21570414
[TBL] [Abstract][Full Text] [Related]
8. Proliferation rate but not mismatch repair affects the long-term response of colon carcinoma cells to 5FU treatment.
Choudhary B; Hanski ML; Zeitz M; Hanski C
Cancer Lett; 2012 Jul; 320(1):56-64. PubMed ID: 22266192
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines.
Wei SC; Lin YS; Tsao PN; Wu-Tsai JJ; Wu CH; Wong JM
J Formos Med Assoc; 2004 Aug; 103(8):599-606. PubMed ID: 15340658
[TBL] [Abstract][Full Text] [Related]
10. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
11. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
Yan T; Berry SE; Desai AB; Kinsella TJ
Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells.
Goel A; Chang DK; Ricciardiello L; Gasche C; Boland CR
Clin Cancer Res; 2003 Jan; 9(1):383-90. PubMed ID: 12538492
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.
Hawn MT; Umar A; Carethers JM; Marra G; Kunkel TA; Boland CR; Koi M
Cancer Res; 1995 Sep; 55(17):3721-5. PubMed ID: 7641183
[TBL] [Abstract][Full Text] [Related]
15. Erybraedin C and bitucarpin A, two structurally related pterocarpans purified from Bituminaria bituminosa, induced apoptosis in human colon adenocarcinoma cell lines MMR- and p53-proficient and -deficient in a dose-, time-, and structure-dependent fashion.
Maurich T; Iorio M; Chimenti D; Turchi G
Chem Biol Interact; 2006 Feb; 159(2):104-16. PubMed ID: 16271357
[TBL] [Abstract][Full Text] [Related]
16. A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.
Alves IT; Cano D; Böttcher R; van der Korput H; Dinjens W; Jenster G; Trapman J
Oncotarget; 2017 Jan; 8(4):6043-6056. PubMed ID: 27907910
[TBL] [Abstract][Full Text] [Related]
17. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
18. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine.
Carethers JM; Hawn MT; Chauhan DP; Luce MC; Marra G; Koi M; Boland CR
J Clin Invest; 1996 Jul; 98(1):199-206. PubMed ID: 8690794
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermia effects on Hsp27 and Hsp72 associations with mismatch repair (MMR) proteins and cisplatin toxicity in MMR-deficient/proficient colon cancer cell lines.
Sottile ML; Losinno AD; Fanelli MA; Cuello-Carrión FD; Montt-Guevara MM; Vargas-Roig LM; Nadin SB
Int J Hyperthermia; 2015; 31(5):464-75. PubMed ID: 26043026
[TBL] [Abstract][Full Text] [Related]
20. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
